STRIVE TM What Is the Evidence That Critical Pathways Work? UCLA Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) ACC Guidelines Applied.

Slides:



Advertisements
Similar presentations
ACTION Registry (Acute Coronary Treatment and Intervention Outcomes Network) Initial Report 1st Quarter 2007 Results Report prepared by: www. ncdr.com.
Advertisements

Patient Oriented Therapy Non STE ACS
© 2010, American Heart Association. All rights reserved. Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute.
© 2010, American Heart Association. All rights reserved. Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained.
Decline in the Use of Drug-Eluting Stents for Patients With NSTEMI Undergoing PCI: Results From the CRUSADE and ACTION Registries Matthew T. Roe, Christopher.
What Have We Learned from the CRUSADE Registry
Eric D. Peterson, MD, MPH Professor of Medicine, Vice Chair for Quality Duke University Medical Center Associate Director & Director of CV Research Duke.
“Influence of Stroke Subtype on Quality of Care in The Get With The Guidelines-Stroke Program” Eric E. Smith, MD, MPH; Li Liang PhD; Adrian F Hernandez,
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Rationale and Design of the Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) at the University of California Los Angeles Gregg C. Fonarow,
“Adjunctive Therapy” Non ST segment elevation ACS Dr M R Thomas King’s College Hospital. Advanced Angioplasty 2002.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained Over Time? A Longitudinal Comparison of GWTG-CAD.
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
Closing the CHD Treatment GAP Saving Lives Through Better Implementation of Secondary Prevention Measures.
© American Heart Association 2001 Nathan D. Wong, PhD, FACC.
“Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute Myocardial Infarction and Heart Failure Paul A Heidenreich,
Download from Slide 1 AGGRASTAT ® † (tirofiban, MSD) to ZOCOR ™ † (simvastatin, MSD) (A to Z) Trial Results from the AGGRASTAT.
Current State of Use of Evidence- Based Therapies for Acute Coronary Syndromes Strategies to Improve Implementation of Guidelines-Based Care Strategies.
Unstable Angina /Non-ST Elevation Myocardial Infarction Critical Pathway Toolkit Adapted from Dr Chris Cannon STRIVE Scientific Committee – 2008 Based.
QI ACTION Registry-Get With The Guidelines The Mission Lifeline Data Solution Kathleen O’Neill, MHA Senior Director, Quality Initiatives IL & SD American.
Amr Hassan Mostafa, MD, FSCAI A. Professor of Cardiology Cairo University Cairo, Egypt Egypt Combat MI, March 24-25, Cairo Sheraton.
CRUSADE: A National Quality Improvement Initiative CRUSADE: A National Quality Improvement Initiative Can Rapid Risk Stratification of Unstable Angina.
Slide 1 AGGRASTAT ™ † (tirofiban, MSD) to ZOCOR ™ † (simvastatin, MSD) (A to Z) Trial Results from the AGGRASTAT Phase † Trademarks of Merck & Co., Inc.,
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
ACUTE MYOCARDIAL INFARCTION Team Membership Clinical Departments: Cardiology, Cardiovascular Surgery, Emergency Medical Services Hospital Departments:
1 Acute Myocardial Infarction and the Role of Critical Pathways Christopher Cannon, M.D. Brigham and Women’s Hospital Boston.
” “The Dissociation Between Door-to- Balloon Time Improvement and Improvements in Other Acute Myocardial Infarction Care Processes and Patient Outcomes”
ACS Clinical Pathway. Who? Pts with Acute Ischemic Heart Disease now described as having ACS.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
ACTION Registry-GWTG Results: January 1, 2009 – December 31, 2009.
Background Current guideline recommend an early invasive strategy for NSTEMI patients (Class IIA). However, 67% US hospitals have no catheterization capability.
Clinical Insights, Risk Stratification, and Enhancing Outcomes.
Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.
ACTION Registry. Objectives of the NCDR Registries Provide data standardization Provide data that is –Relevant, Credible, Timely, Actionable Present real.
0009COR1 A CRUSADE to Improve Quality of Care for ACS Patients Eric D. Peterson, MD, MPH Associate Professor of Medicine Director of CV Outcomes and Quality.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
6/04 CRUSADE: A National Quality Improvement Initiative C an R apid Risk Stratification of U nstable Angina Patients S uppress AD verse Outcomes with E.
TCT Presentation October 2006 Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors.
Pharmacotherapy in acute coronary syndromes Perspective from first line and regional hospitals in Czech Republic Cardionale, Petr Jansky.
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.
Antiplatelet Interventions in Acute Coronary Syndromes.
Trends in the Quality of Care of Patients with Acute Myocardial Infarction: The National Registry of Myocardial Infarction from 1990 to 2006 Bimal R. Shah,
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
Impact of Prior Myocardial Infarction Among Patients with Acute Myocardial Infarction Treated in Contemporary Practice: A Report from the ACTION Registry.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Acute Myocardial Infarction February 8, 2006.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.
Management of Patients with NSTE ACS Latest Insights from CRUSADE A National Quality Improvement Initiative Eric D. Peterson, MD, MPH Duke Clinical Research.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: A guide to therapeutic decision-making in patients.
SECONDARY PREVENTION IN HEART DISEASE CATHY QUICK AUBURN UNIVERSITY/AUBURN MONTGOMERY EBP III.
Management Strategies for Post-Intervention in Patients with CAD VBWG.
Risk Stratification of Chest Pain: Best Practices
Copyright © 2008 American Medical Association. All rights reserved.
Brief History on Mission: Lifeline
European Heart Association Journal 2007 April
The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,
Section F: Clinical guidelines
2006 CRUSADE 2nd Quarter Results
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Global Registry of Acute Coronary Events: GRACE
What oral antiplatelet therapy would you choose?
What Have We Learned from the CRUSADE Registry
Quality Improvement Programs and Critical Pathways
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

STRIVE TM What Is the Evidence That Critical Pathways Work? UCLA Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) ACC Guidelines Applied in Practice (GAP) initiative AHA “Get With The Guidelines” program CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines)

STRIVE TM CHAMP Study: UCLA Designed to determine whether physician/patient compliance with preventive therapies can be improved through a hospital- initiated program Tracked initiation of aspirin, β-blocker, ACE inhibitor, statins Used preprinted orders, guidelines, lectures, discharge forms Population: patients with symptomatic atherosclerosis treated at university-associated teaching hospital Methods: no specific algorithms used before CHAMP ( ) National guidelines (ACC/AHA, NCEP ATP I and ATP II) used in CHAMP ( ) Evaluation: treatment rates and clinical outcomes pre-CHAMP and CHAMP in patients hospitalized for acute MI Fonarow GC, Gawlinski A. Am J Cardiol. 2000;85(3A):10A-17A. Cardiac Hospitalization Atherosclerosis Management Program

STRIVE TM Discharge Medications at UCLA Compared With 1437 NRMI Hospitals Aspirin β-blockers ACEIStatins /99 Post-CHAMP (UCLA) 00/01 Post-CHAMP (UCLA) 92/93 Pre-CHAMP (UCLA) 94/95 Post-CHAMP (UCLA) 96/97 Post-CHAMP (UCLA) Fonarow GC, et al. Am J Cardiol. 2001;87: [NRMI Hospitals 00/01 (n=154,602)] Nat’l Benchmark Utilization Rate (%) CHAMP Over an 8-Year Period: Rapid and Sustained Improvement, Superior to National Benchmarks

STRIVE TM Adapted from Mehta RH, et al. JAMA. 2002;287: At AdmissionAt Discharge Pre-GAP Post-GAP Aspirin Usage (%) P=.02 P=.002 ACC’s Guidelines Applied in Practice (GAP) Initiative: Impact on Aspirin Usage at Admission and Discharge

STRIVE TM Adapted with permission from Mehta RH, et al. JAMA. 2002;287: Quality Adherence (%) Preintervention No Tool Use Tool Use Postintervention Aspirin β-Blocker LDL-C No. of Ideal Patients P=.004P=.001 Early Quality Indicators and Standard Admission Orders GAP Initiative: Adherence Improves With Tool Use

STRIVE TM GAP Initiative: Changes in Mortality Before and After GAP Project Eagle KA, et al. J Am Coll Cardiol. 2005;46: In-hospital Mortality 30-d Mortality 1-yr Mortality % Baseline Post-GAP P=.017 P=.001 P=.004

STRIVE TM AHA “Get With The Guidelines” Program Components Training materials for hospital staff Patient education materials Assistance in creating multidisciplinary team Secondary prevention guidelines CME workshops Sample materials (care maps, discharge protocols, discharge forms) American Heart Association Web site. Get With The Guidelines. Available at:

STRIVE TM Clinical/Lab: 8 clicks Clinical/Lab: 8 clicks Interactively checks patient’s data with the AHA Guidelines Discharge meds and interventions: 7 clicks Discharge meds and interventions: 7 clicks Demographics: 6 clicks AHA Tool: Simple One-Page, Online Form American Heart Association Web site. Get With The Guidelines. Available at:

STRIVE TM Rehab/ Exercise Baseline4-6 Months9-12 MonthsBenchmark* Intervention Smoking Counsel LDL-CBP Control Proportion of Patients *Benchmarks established by CMS AND NRMI. Reprinted with permission from the American Heart Association Web site. Get With The Guidelines. Available at: Get With The Guidelines 12-Month Pilot Results: 85 New England Hospitals N=1709

STRIVE TM CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines Nationwide quality improvement (QI) initiative –Up to 600 participating hospitals Collaborative effort between emergency medicine, cardiology, hospital QI, academia, and industry Focused on improving the care of NSTEMI ACS patients Adapted from CRUSADE Overview Available at: © 2005 Duke Clinical Research Institute. Used with permission.

STRIVE TM CRUSADE: Inclusion Criteria Ischemic symptoms lasting >10 minutes within previous 24 hours and at least one of the following: –Positive cardiac markers CK-MB or Tnl/TnT above ULN Positive bedside troponin assay –ST-segment ECG changes ST-segment depression >0.5 mm Transient ST-segment elevation 0.6–1 mm (lasting <10 mins) Transfer patients (with any of the above) must arrive at CRUSADE hospital within 24 hours of symptoms © 2005 Duke Clinical Research Institute. Used with permission. Available at

STRIVE TM Goals for CRUSADE Aspirin –Clopidogrel  -Blocker Heparin (UFH or LMWH) GP IIb/IIIa Inhibitor –Cath/PCI Aspirin Clopidogrel  -Blocker ACE Inhibitor Statin/Lipid Lowering Smoking Cessation Cardiac Rehabilitation Acute Therapy Discharge Therapy 2002 ACC/AHA Guidelines Update. Adapted from 2005 CRUSADE 2nd Quarter Results. Available at: © 2005 Duke Clinical Research Institute. Used with permission. Improve Adherence to ACC/AHA Guidelines Improve Patient Outcomes

STRIVE TM Hospital Presentation Characteristics in CRUSADE: July 1, 2005–June 30, 2006 (n=31,665) Qualifying criteria ST-segment depression 28% Transient ST-segment elevation 5% Positive cardiac markers 93% Baseline cardiac markersDrawnPositive CK-MB82%75% TnT/TnI99%91% Presenting characteristics Tachycardia23% Hypotension 4% Signs of CHF23% Adapted from 2006 CRUSADE Results. Available at: © 2006 Duke Clinical Research Institute. Used with permission.

STRIVE TM Baseline Characteristics: CRUSADE vs ACS Clinical Trials VariablePURSUITCURESYNERGYCRUSADE (n = 9461)(n = 12,562)(n = 9975)(n = 180,842) Mean age ± SD (yrs)63 ± 1163 ± 1267 ± 1167 ± 14 Female sex (%) Diabetes mellitus (%) Prior MI (%) Prior CHF (%) Prior PCI (%)1318*2021 Prior CABG (%)1218*1719 ST depression (%) N Engl J Med. 1998;339: N Engl J Med. 2001;345: JAMA. 2004:292: CRUSADE cumulative through June 30, N Engl J Med. 1998;339: N Engl J Med. 2001;345: JAMA. 2004:292: CRUSADE cumulative through June 30, 2006.

STRIVE TM CRUSADE: Trends in Acute Therapy Adherence Adapted from 2006 CRUSADE Results. Available at: © 2006 Duke Clinical Research Institute. Used with permission. 96% 90% 84% 46% 97% 93% 88% 50% 0% 25% 50% 75% 100% Antiplateletβ-BlockerHeparinGP IIb/IIIa Inhibitor Quarter 3-05Quarter 4-05Quarter 1-06Quarter 2-06 Quarter 3, 2005, through Quarter 2, 2006.

STRIVE TM CRUSADE Data: July 1, 2005-June 30, 2006 (n=31,665) CRUSADE: Invasive Cardiac Procedures July 1, 2005 – June 30, 2006 (n=31,665) (Among Patients Without Contraindications to Cath) Adapted from 2006 CRUSADE Results. Available at: © 2006 Duke Clinical Research Institute. Used with permission. 83% 67% 53% 38% 12% 0% 20% 40% 60% 80% 100% Cath <48 hr PCIPCI <48 hrCABG

STRIVE TM CRUSADE: Trends in Discharge Therapy Adherence Quarter 3, 2005, through Quarter 2, 2006 Adapted from 2006 CRUSADE Results. Available at: © 2006 Duke Clinical Research Institute. Used with permission. 94% 72% 91% 64% 89% 74% 94% 66% 88% 95% 0% 25% 50% 75% 100% AspirinClopidogrelβ-BlockerACE InhibitorLipid- Lowering Agent Quarter 3-05Quarter 4-05Quarter 1-06

STRIVE TM CRUSADE: Trends in Discharge Recommendations Adherence 84% 81% 62% 84% 62% 92% 0% 25% 50% 75% 100% Smoking Cessation Counseling Dietary ModificationCardiac Rehabilitation Referral Quarter 3-06Quarter 4-06Quarter 1-06Quarter 2-06 Quarter 3, 2005, through Quarter 2, Adapted from 2006 CRUSADE Results. Available at: © 2006 Duke Clinical Research Institute. Used with permission.

STRIVE TM CRUSADE: Overall Guideline Adherence Trends Over Time Available at © 2006 Duke Clinical Research Institute. Used with permission. Quarter Quarter Quarter Quarter Quarter % 73.0% 78.0% 80.8% 83.2% 0% 25% 50% 75% 100%

STRIVE TM Performance Matters! Association Between Hospital Guideline Adherence and In-hospital Mortality in CRUSADE Adapted with permission from Peterson ED, et al. JAMA.2006;295: NSTE ACS = non-ST-segment elevation ACS; NSTEMI = non-ST-segment elevation MI In-Hospital Mortality, % Hospital Composite Guideline Adherence Quartiles NSTE ACS In-Hospital Mortality, % Hospital Composite Guideline Adherence Quartiles NSTEMI CRUSADE = Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines.

STRIVE TM NRMI. Available at: Get With The Guidelines. Available at: ACC National Cardiovascular Data Registry. Available at: GRACE. Available at: CRUSADE. Available at: REACH. Available at: Importance of Data-Collection Registries Track adherence to guidelines Support local quality-improvement programs Compare practice patterns/outcomes with national benchmarks Comply with regulatory requirements Provide research data Major data-collection registries –NRMI –AHA “Get With The Guidelines” Patient Management Tool –ACC National Cardiovascular Data Registry –GRACE –CRUSADE –REACH

STRIVE TM CRUSADE: Latest Results in NSTEMI ACS in US: Conclusions Care for NSTEMI ACS is improving: –Continued progress in adherence to ACC/AHA Guidelines for both acute and discharge treatments –More early cath, leading to earlier discharge Yet opportunities for improvement persist –Largest gaps: acute GP IIb/IIIa, D/C ACE, clopidogrel –“Right dosing” to reduce adverse events And can lead to even better patient outcomes! Available at © 2005 Duke Clinical Research Institute. Used with permission.

STRIVE TM Conclusions Gap between knowledge of guidelines and practice Several studies show: –Critical pathways interventions improve care and improve patient outcomes Need local champions, implementation plan, and action!